Covalent inhibitors: a rational approach to drug discovery
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
In this review we provide a brief historic overview of covalent inhibitors and summarize recent advances focusing on developments in the last decade. Applications in challenging targets and future perspectives are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past 30 years, the rational design of covalent drugs has garnered increased interest, and covalently targeting non-conserved amino acids to increase selectivity has become commonplace2,5.”
From Advances in covalent drug discovery (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Covalent drugs also exhibit impressive performance in selective targeting,521 potentially providing novel inhibitory approaches for kinases such as CK1, which have previously only been targeted with non-covalent ATP competitive inhibitors.522”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
The cited source says what the claim attributes to it.
In the citing paper
“Covalent inhibitors, which form covalent bonds with their target proteins, rely on the specificity and stability of these interactions to exhibit superior potency, selectivity, and duration of action. This mechanism offers patients a convenient therapeutic option.521,565”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
PENICILLIN-BINDING PROTEINS AND THE MECHANISM OF ACTION OF BETA-LACTAM ANTIBIOTICS
Waxman, D. J., & Strominger, J. L. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.004141 · Cited by 721
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · cited 1×
“In 2013, Walter et al.13 showed that a novel covalent inhibitor, CO-1686, inhibits a drug-resistance mutant of T790M EGFR.”
Background
Cited by
Items 101–200 of 403
A targeted covalent inhibitor of p97 with proteome-wide selectivity
Ye, Z., Wang, K., Chen, L., Jin, X., Chen, H., Tang, G., Yao, S. Q., Feng, Z., & Zhang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.003 · Cited by 19
Identification of the first structurally validated covalent ligands of the small GTPase RAB27A
Jamshidiha, M., Lanyon‐Hogg, T., Sutherell, C. L., Craven, G. B., Tersa, M., Vita, E. D., Brustur, D., Pérez‐Dorado, I., Hassan, S., Petracca, R., et al. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00225b · Cited by 19
Westberg, M., Su, Y., Zou, X., Lin, N., Hurst, B. L., Tarbet, E. B., & Lin, M. Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.15.275891 · Cited by 20
“those with aldehydes (26–29), and examples have progressed to late-stage clinical trials or regulatory approval (30, 31).”
BackgroundCavina, L., Bouma, M. J., Gironés, D., & Feiters, M. C. (2024) · Molecules · doi:10.3390/molecules29174047 · Cited by 17
“Covalent viral protease inhibitors have already been successfully marketed, e.g., Narlaprevir, Arlansa ® against HCV (hepatitis C virus, from another genus of the Flaviviridae ) [66] and Nirmatrelvir, Paxlovid ® against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) [67].”
MethodZhang, Z., Qian, H., Xu, R., Duan, Q., Wang, Y., Fu, T., Wu, X., Sha, C., Wu, Q., Wang, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c11823 · Cited by 17
Discovery of Covalent Ligands with AlphaFold3
Shamir, Y., Gabizon, R., Rogel, A., Lin, D. Y.-W., Andreotti, A. H., & London, N. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c22222 · Cited by 22
“We further characterized the three main hits � YS1, YS2, and YS3, and used ibrutinib, an FDA-approved drug for BTK, as a control 53 (Figure 3C).”
Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
Diogo, M. A., Cabral, A. G. T., & de Oliveira, R. B. (2024) · Pathogens · doi:10.3390/pathogens13100825 · Cited by 20
“Moreover, covalent drugs are less susceptible to resistance caused by mutations, as the formed bond typically involves the nucleophilic residue essential for enzymatic catalysis [90,91].”
BackgroundLin, C.-C., Hoo, S. Y., Ma, L., Lin, C., Huang, K.-F., Ho, Y.-N., Sun, C.-H., Lee, H., Chen, P.-Y., Shu, L., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03409-6 · Cited by 20
3-chymotrypsin-like protease in SARS-CoV-2
Adem, K. A., Ferreira, J. C., Villanueva, A. J., Fadl, S., El-Sadaany, F., Masmoudi, I., Gidiya, Y., Gurudza, T., Cardoso, T. H. S., Saksena, N. K., et al. (2024) · Bioscience Reports · doi:10.1042/bsr20231395 · Cited by 18
“The choice between covalent and non-covalent inhibition depends on the characteristics of the target enzyme, the desired duration of action, and the need for selectivity [192].”
Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation
Yu, W., Weber, D. J., & MacKerell, A. D. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00232 · Cited by 16
“During the binding process (3, 4), a ligand will first noncovalently interact with the protein in an equilibrium, Keq = kon/koff, which in the context of binding free energies is modeled as LGFEEq.”
Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors
Xerxa, E., Laufkötter, O., & Bajorath, J. (2023) · Molecules · doi:10.3390/molecules28155805 · Cited by 16
“Although most CPKIs have been discovered serendipitously, drug design using reversible non-covalent ligands as templates [20,21] or fragment-based design [22,23] and tethering approaches [24] are becoming common practice in CPKI discovery and development.”
BackgroundReversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease
Chen, J., Farraj, R. A., Limonta, D., Dakhili, S. A. T., Kerek, E. M., Bhattacharya, A., Reformat, F. M., Mabrouk, O. M., Brigant, B., Pfeifer, T. A., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105341 · Cited by 16
“Despite previously being classi fi ed as PAIN molecules (62), modern covalent inhibitors are emerging with advantages over traditional mechanistic inhibitors, including increased potency, the ability to target shallow binding sites, and defense against drug resistance (61).”
BackgroundHasan, M. N., Ray, M., & Saha, A. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04710 · Cited by 17
Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality
Li, Z., Jiang, J., Ficarro, S. B., Beyett, T. S., To, C., Tavares, I., Zhu, Y., Li, J., Eck, M. J., Janne, P. A., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01245 · Cited by 19
Aziz, U. B. A., Saoud, A., Bermúdez, M., Mieth, M., Atef, A., Rudolf, T., Arkona, C., Trenkner, T., Böttcher, C., Ludwig, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47741-3 · Cited by 16
“Michael acceptors like PB-3 ful fi ll essential selectivity and stability criteria of covalent drugs 39,46 and thus can be considered as lead structures for the pre-clinical development of PLY inhibitors, which might constitute an effective anti-virulence strategy against PLY-mediated pathogenesis.”
Oyedele, A.-Q. K., Ogunlana, A. T., Boyenle, I. D., Ibrahim, N. O., Gbadebo, I. O., Owolabi, N., Ashiru, M. A., Francis, A. C., Eyinade, O., & Adelusi, T. I. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10534-1 · Cited by 18
EFMC: Trends in Medicinal Chemistry and Chemical Biology
Auberson, Y. P., Arimondo, P. B., Duca, M., Essig, S., Grether, U., Rufer, A. C., Sbardella, G., Schopfer, U., Torrens, A., van der Stelt, M., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202200690 · Cited by 18
Exploring the landscape of post-translational modification in drug discovery
Cao, Y., Yu, T., Zhu, Z., Zhang, Y., Sun, S., Li, N., Gu, C., & Yang, Y. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108749 · Cited by 21
Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets
Lee, J., & Park, S. B. (2022) · Pharmaceuticals · doi:10.3390/ph15121478 · Cited by 17
“To this end, Singh and co-workers proposed a new strategy using targeted covalent inhibitors (TCIs) in 2011 (Figure 2b) [9].”
BackgroundTargeted degrader technologies as prospective SARS-CoV-2 therapies
Khurshid, R., Schulz, J. M., Hu, J., Snowden, T. S., Reynolds, R. C., & Schürer, S. C. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103847 · Cited by 14
Sousa, J. L. C., Albuquerque, H. M. T., & Silva, A. M. S. (2023) · Pharmaceuticals · doi:10.3390/ph16121668 · Cited by 16
Martins, D. M., Fernandes, P. O., Vieira, L. A., Maltarollo, V. G., & Moraes, A. H. (2024) · ChemBioChem · doi:10.1002/cbic.202400296 · Cited by 15
Li, Y., Han, L., & Zhang, Z. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.02.018 · Cited by 16
“Recently, the strategy of developing covalent inhibitors [23,24] has received wide attention.”
BackgroundAdvances in UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA) Covalent Inhibition
de Oliveira, M. V. D., Furtado, R. M., da Costa, K. S., Vakal, S., & Lima, A. H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.889825 · Cited by 15
“Its mode of action is related to the covalent binding to the thiol group of Cys115 residue in the active site of MurA (Kahan et al., 1974; Falagas et al., 2016; Sutanto et al., 2020; Scarpino et al., 2021).”
BackgroundAlcala‐Torano, R., Islam, M., Cika, J., Lam, K. H., Jin, R., Ichtchenko, K., Shoemaker, C. B., & Deventer, J. A. V. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00574 · Cited by 15
Ren, P., Yu, C., Zhang, R., Nie, T., Hu, Q., Li, H., Zhang, X., Zhang, X., Li, S., Liu, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115129 · Cited by 15
“Therefore, 2,3,5-substituted [1,2,4]-thiadiazole group can be applied as a potential electrophilic ‘warhead’ for the design of covalent inhibitors.”
InfluentialTherapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
Li, L., Meyer, C., Zhou, Z.-W., Elmezayen, A., & Westover, K. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167626 · Cited by 14
Upadhyay, T., Woods, E. C., Ahator, S. D., Julin, K., Faucher, F. F., Uddin, M. J., Hollander, M. J., Pedowitz, N. J., Abegg, D., Hammond, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60367-3 · Cited by 17
“Notably, covalent inhibitors can be engineered to have exquisite selectivity and improved ef fi ciency due to prolonged inhibition of the desired target 18,19 .”
Regulation of Cardiac PKA Signaling by cAMP and Oxidants
Cuello, F., Herberg, F. W., Σταθοπούλου, Κ., Henning, P., & Diering, S. (2021) · Antioxidants · doi:10.3390/antiox10050663 · Cited by 18
Zheng, M., Zhang, Y., Xu, Y., Han, Y., Wu, Y., & Kang, J. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00188 · Cited by 13
Guo, L., Li, J., Tian, Y., Zhao, Y., Pang, X., & Yan, A. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10696-6 · Cited by 14
“In this study, an inhibitor with a covalent bond would be assumed that it is highly active and has alpha, beta-unsaturated carbonyl substructure so that it can bind Cys481 to form a covalent bond [29].”
Development of covalent chemogenetic K2P channel activators
Deal, P. E., Lee, H., Mondal, A., Lolicato, M., Mendonça, P. R. F., Black, H., Jang, S., ElHilali-Pollard, X., Bryant, C., Isacoff, E. Y., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.06.006 · Cited by 13
Reimer, B. M., Awoonor‐Williams, E., Golosov, A. A., & Horn̆ák, V. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01281 · Cited by 16
High-throughput hit identification with acoustic ejection mass spectrometry
Wen, X., & McLaren, D. G. (2025) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2025.100245 · Cited by 13
Zhou, B., Gao, Y., Zhao, H., Liu, B., Zhang, H., Fang, C., Yuan, H., Wang, J., Li, Z., Zhao, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58410-4 · Cited by 13
“5a), consistent with BTZ being one of the clinically approved covalent protease inhibitors 45,46 .”
Gold-Catalyzed Access to Isophosphinoline 2-Oxides
Hariri, M., Darvish, F., Ndong, K.-P. M. M., Sechet, N., Chacktas, G., Boosaliki, H., Do, M. L. T., Maguene, G. M., Lebibi, J., Burilov, A. R., et al. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00648 · Cited by 14
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
Lovell, A. R., Jammal, N., & Bose, P. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221116577 · Cited by 15
Targeting Ribonucleases with Small Molecules and Bifunctional Molecules
Borgelt, L., & Wu, P. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00191 · Cited by 13
Anhydrous Carbene Insertion Reactions: A Synthetic Platform for DNA‐Encoded Library
Su, X., Shi, W., Zhang, Y., Xiao, W., Xue, J., Zhu, X., Yan, M., & Zhang, X. (2023) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202300844 · Cited by 13
Abadi, M. H. H. E., Ghasemlou, A., Bayani, F., Sefidbakht, Y., Vosough, M., Mozaffari‐Jovin, S., & Uversky, V. N. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2308769 · Cited by 17
“Table 1 presents a detailed comparison of covalent and non-covalent inhibitors, highlighting their advantages and disadvantages (Sutanto et al., 2020; Xu et al., 2006).”
Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents
Zhou, C., Sun, C., Zhou, W., Tian, T., Schultz, D., Wu, T., Yu, M., Wu, L., Pi, L., & Li, C. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00925 · Cited by 13
João, E. E., Lopes, J. R., Guedes, B. F. R., Sanches, P. R. D. S., Chin, C. M., dos Santos, J. L., & Scarim, C. B. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107914 · Cited by 12
Deciphering the landscape of allosteric glutaminase 1 inhibitors as anticancer agents
Vagaggini, C., D’Ursi, P., Poggialini, F., Fossa, P., Francesconi, V., Trombetti, G., Orro, A., Dreassi, E., Schenone, S., Tonelli, M., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108523 · Cited by 17
Guan, I. A., Williams, K., Pan, J., & Liu, X. (2021) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202100036 · Cited by 14
Heriberto, V. M. L., Mendoza-Figueroa, H. L., García-Vázquez, J. B., Correa‐Basurto, J., & García‐Machorro, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073987 · Cited by 12
“In this second step, the covalent bond is formed in situ, generating a protein–ligand covalent complex [28].”
BackgroundFaris, A., Ibrahim, I. M., Kamaly, O. M. A., Saleh, A., & Elhallaoui, M. (2023) · Molecules · doi:10.3390/molecules28155914 · Cited by 14
“Software In the present investigation, a comprehensive array of computational methodologies was employed to identify potential ligands exhibiting enhanced activity towards a specific target [30,46].”
MethodWarhead Reactivity Limits the Speed of Inhibition of the Cysteine Protease Rhodesain
Johé, P., Jung, S., Endres, E., Kersten, C., Zimmer, C., Ye, W., Sönnichsen, C., Hellmich, U. A., Sotriffer, C., Schirmeister, T., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00911 · Cited by 13
Rothweiler, E. M., Brennan, P. E., & Huber, K. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0396 · Cited by 13
PROTACting the kinome with covalent warheads
Chatterjee, D. R., Kapoor, S., Jain, M., Das, R., Chowdhury, M. G., & Shard, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103417 · Cited by 12
A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.
King, J., Smithers, L., Vrielink, A., Lesterhuis, W., & Piggott, M. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02192 · Cited by 12
Covalent ligands of nuclear receptors
Rajan, S., & Yoon, H. S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115869 · Cited by 11
Ying, T., Hu, H., Wu, X.-W., Xu, X.-L., Lv, J., Zhang, S., Wang, H., Hou, W., Wei, B., & Rao, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117571 · Cited by 11
Recent developments in predicting CYP-independent metabolism
Dhuria, N. V., Haro, B., Kapadia, A. K. B., Lobo, K. A., Matusow, B., Schleiff, M. A., Tantoy, C., & Sodhi, J. K. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1923728 · Cited by 11
Liang, X., Sun, C., Li, C., Yu, H., Wei, X., Liu, X., Bao, W., Shi, Y., Sun, X., Khamrakulov, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00466 · Cited by 11
A patent and literature review of CDK12 inhibitors
Tang, R., Liu, J., Li, S., Zhang, J., Yu, C., Liu, H., Chen, F., Lv, L., Zhang, Q., Yuan, K., et al. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2126765 · Cited by 12
Azad, I., Anand, P., Dwivedi, A. K., Saha, S., & Akhter, Y. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134541 · Cited by 11
Recent progress of oridonin and its derivatives for cancer therapy and drug resistance
Guan, Y.-F., Liu, X., Pang, X., Liu, W.-B., Yu, G.-X., Li, Y.-R., Zhang, Y., Song, J., & Zhang, S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02779-6 · Cited by 11
SCARdock: A Web Server and Manually Curated Resource for Discovering Covalent Ligands
Song, Q., Zeng, L., Zheng, Q., & Liu, S. (2023) · ACS Omega · doi:10.1021/acsomega.2c08147 · Cited by 12
Reaction mechanism – explored with the unified reaction valley approach
Kraka, E., Antonio, J. J., & Freindorf, M. (2023) · Chemical Communications · doi:10.1039/d3cc01576a · Cited by 10
Ngo, H., Wen, Y. W., Pisupati, S., Huang, W., & Mandlekar, S. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3390 · Cited by 15
“4,10 As covalent inhibitor drugs garnered more popularity, undesired off-target effects associated with these drugs also became apparent, which led to clinical safety concerns.”
Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs
Weissberger, D., Stenzel, M. H., & Hunter, L. (2024) · Molecules · doi:10.3390/molecules29204949 · Cited by 12
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 14
“Among the disadvantages are off-target toxicity and the risk of having excess immunogenicity [120].”
Mills, B., Isaac, R. E., & Foster, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01721 · Cited by 11
Lu, G., Ou, K., Zhang, Y., Zhang, H., Feng, S., Yang, Z., Guo, S., Liu, J., Wei, S., Pan, S., et al. (2023) · Molecules · doi:10.3390/molecules28020570 · Cited by 10
“Inhibitors that form covalent bonds with their targets have traditionally been considered highly adventurous due to their potential off-target effects and toxicity concerns [13,14].”
BackgroundStructure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor
Liang, Q., Wang, B., Zou, F., Guo, G., Wang, W., Wang, W., Liu, Q., Shen, L., Hu, C., Wang, W., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115411 · Cited by 10
Bhujbal, S. P., & Hah, J. (2023) · Pharmaceuticals · doi:10.3390/ph16091295 · Cited by 10
“In 2011, Singh and colleagues introduced a novel strategy utilizing targeted covalent inhibitors In 2011, Singh and colleagues introduced a novel strategy utilizing targeted covalent inhibitors (TCIs) [28].”
Data-oriented protein kinase drug discovery
Xerxa, E., & Bajorath, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116413 · Cited by 12
Electrophile Determines Cellular Phenotypes among XPO1-Targeting Small Molecules
Chen, Y., Shen, Y., Yan, D. F., Ghazala, M., de Gialluly, M. A. S., Srinivasan, R., Farrar, A. N., Friedrich, R. M., & Adams, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00754 · Cited by 10
Tabuchi, Y., Watanabe, T., Katsuki, R., Ito, Y., & Taki, M. (2021) · Chemical Communications · doi:10.1039/d1cc01773j · Cited by 10
Profiling the Proteome-Wide Selectivity of Diverse ElectrophilesPreprint
Zanon, P. R. A., Yu, F., Musacchio, P. Z., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14186561 · Cited by 13
Peng, Q., & Weerapana, E. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.11.010 · Cited by 9
Covalent aptamers: agents with promising therapeutic and diagnostic potential
Albright, S., Boette, J., Cacace, M., & Deiters, A. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00133a · Cited by 9
Kwong, A. J., Pham, T. D., Oelschlager, H. E., Munshi, H. G., & Scheidt, K. A. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00376 · Cited by 10
Solid Phase Synthesis of Fluorosulfate Containing Macrocycles for Chemoproteomic Workflows
Faucher, F. F., Abegg, D., Ipock, P., Adibekian, A., Lovell, S., & Bogyo, M. S. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202300020 · Cited by 11
Druggable Sterol Metabolizing Enzymes in Infectious Diseases: Cell Targets to Therapeutic Leads
Nes, W. D., Chaudhuri, M., & Leaver, D. J. (2024) · Biomolecules · doi:10.3390/biom14030249 · Cited by 10
Improving p K a Predictions with Reparameterized Force Fields and Free Energy Calculations
Wilson, C. J., Gapsys, V., & de Groot, B. L. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c00031 · Cited by 11
Cha, H., Chai, J. Y., Kim, H. B., & Yoon, D. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob00129a · Cited by 9
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IX
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.3 · Cited by 10
Awoonor‐Williams, E., & Abu‐Saleh, A. A. A. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c00310 · Cited by 8
The covalent docking software landscape: features and applications in drug design
Singh, N., Vayer, P., & Villoutreix, B. O. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf697 · Cited by 10
“Historically, many covalent drugs were discovered serendipi-tously,suchas aspirin (marketed over 100 years ago) and penicillin (discovered in 1928) [6].”
Song, J., Pan, C., Li, J., Bai, R., Zeng, Z., Han, Y., Chen, Z., Hou, W., Li, Y., & Ruan, B. H. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00302 · Cited by 8
Shen, F., Yang, W., Zhang, K., Jiao, Y., Cui, J. Z., Hou, Y., & Bai, G. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108203 · Cited by 8
Issahaku, A. R., & Soliman, M. E. S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220617151552 · Cited by 8
Awoonor‐Williams, E. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp03080b · Cited by 9
Nambiar, M., Xie, Y., Ivanic, J., & Schneider, J. P. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08170 · Cited by 7
Peptide-Based Targeted Covalent Inhibitors
Cao, F., Guo, R.-C., Zhang, Z., & Yu, Z. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18100 · Cited by 8
Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy
Nelson, K. J., Smalley, T. L. J., Messier, T., Gumpena, R., Gandhi, U., Milczarek, S., Habibovic, A., Hoffman, H., Gibson, V., Hondal, R. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady4492 · Cited by 7
“The development of covalent inhibitors has reached a zenith with ~ 30 % of all marketed drugs exploiting this mechanism despite historical concerns for irreversibility and potential toxicity ( 1 ).”
4‐O‐Substituted Glucuronic Cyclophellitols are Selective Mechanism‐Based Heparanase Inhibitors
Borlandelli, V., Armstrong, Z., Nin‐Hill, A., Codée, J. D. C., Raich, L., Artola, M., Rovira, C., Davies, G. J., & Overkleeft, H. S. (2022) · ChemMedChem · doi:10.1002/cmdc.202200580 · Cited by 7
Faris, A., Ibrahim, I. M., Chakraborty, S., Kamaly, O. M. A., Alshawwa, S. Z., & Elhallaoui, M. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230821102836 · Cited by 7
Exploring the binding dynamics of covalent inhibitors within active site of PLpro in SARS-CoV-2
Patel, D. K., Kumar, H., & Sobhia, M. E. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108132 · Cited by 7
Shang, J., Yin, S., Shen, J., Gao, C., Wang, W., Sun, K., Zhu, W., & Fu, P. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c03803 · Cited by 7
UBE2N: Hope on the Cancer Front, How to Inhibit This Promising Target Prospect?
Schwalen, F., Ghadi, C., Ibazizene, L., Khan, S. U., Santos, J. S. O., Weiswald, L., Voisin‐Chiret, A. S., Meryet‐Figuière, M., & Kieffer, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01517 · Cited by 8
Mol’kova, E. A., Shchegravina, E. S., Otvagin, V. F., Kuzmina, N. S., Malysheva, Y. B., Svirshchevskaya, E. V., Zaburdaeva, E. A., & Fedorov, A. Y. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3449-7 · Cited by 7
Hossain, M. A., Brahme, R. R., Miller, B. C., Amin, J., de Barros, M., Schneider, J. L., Auclair, J. R., Mattos, C., Wang, Q., Agar, N. Y. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56985-6 · Cited by 9
“Inpioneeringworktoovercometheselimitations, empirical relationships between PK and PD AUCs were established for a number of drugs 14 including aspirin 15 , pantoprazole 16 , penicillin 17,18 , and anticancer drugs 19 – 21 .”
Serrano-Sterling, C., Iriepa, I., Macias, M. A., Castillo, J., & Becerra, D. (2026) · RSC Advances · doi:10.1039/d5ra07121f · Cited by 6
Kumar, V., Danodia, A. K., Jadhavar, P. S., Mohanty, S. K., & Samanta, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118555 · Cited by 8
Sun, L., Zhu, B., Zuo, K., Bai, L., Lei, J., Li, Y., Liu, X., Pan, X., Li, J., Wu, A., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04253-0 · Cited by 6
“This enables irreversible covalent bonding with specific amino acid residues–such as lysine, tyrosine, and histidine–within target proteins [37–38].”
Arylboronic acids as safe and specific human butyrylcholinesterase inhibitors
dos Santos, E. S. C., Silva, N. A. D. A. E., Gonçalves, K. G., Vale, A. Á. M., de Azevedo-Santos, A. P. S., França, T. C. C., LaPlante, S. R., Resende, J. A. L. C., Romeiro, N. C., Lima, J. A., et al. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135932 · Cited by 6
Xiang, S., Shen, R., Xiang, J., Zhu, N., Gu, J., Shen, J., Zhang, Y., & Ge, H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2327507 · Cited by 7
“Ibrutinib was the first in class approved by the US Food and Drug Administration (FDA) for mantle cell lymphoma (MCL) in 2013, acalabrutinib, approved in 2017, followed by zanubrutinib in 2019 [6].”
BackgroundCrafting Molecular Tools for 15‐Lipoxygenase‐1 in a Single Step
Louka, A., Spacho, N., Korovesis, D., Adamis, K. S., Papadopoulos, C., Kalaitzaki, E.-E., Tavernarakis, N., Neochoritis, C. G., & Eleftheriadis, N. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202418291 · Cited by 7
Metadata
- Authors
- Sutanto, F., Konstantinidou, M., & Dömling, A.
- Affiliations
- University of Groningen (NL)
- Corresponding author
- Dömling, Alexander
- Venue
- RSC Medicinal Chemistry
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 11
- Issue
- 8
- Pages
- 876-884
- ISSN
- 2632-8682 (ISSN-L)
- PMC
- PMC7557570
- OpenAlex
- W3038238188
- Cited by
- 389
- References
- 27
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 72 · 2023: 64 · 2022: 75 · 2021: 48 · 2020: 5
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- RSC Medicinal Chemistry (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (2R01GM097082-05)
- KWF Kankerbestrijding (10504)
- Lembaga Pengelola Dana Pendidikan
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent inhibitors, drug discovery, off-target toxicity, cancer drug targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.